{"component": "definition", "props": {"groups": [{"samples": [{"hash": "iJCjS2utWpq", "uri": "/contracts/iJCjS2utWpq#product-transfer", "label": "Stock Purchase Agreement", "score": 31.3408622742, "published": true}, {"hash": "6Pdkam4i90a", "uri": "/contracts/6Pdkam4i90a#product-transfer", "label": "Stock Purchase Agreement (Conatus Pharmaceuticals Inc)", "score": 24.5564689636, "published": true}, {"hash": "alqArg9mdCV", "uri": "/contracts/alqArg9mdCV#product-transfer", "label": "Stock Purchase Agreement (Conatus Pharmaceuticals Inc)", "score": 24.4496917725, "published": true}], "size": 5, "snippet_links": [{"key": "defined-in-section", "type": "clause", "offset": [3, 21]}], "snippet": "is defined in Section 2.5.3.", "hash": "45c6d058798adf4129706c90a01c8a88", "id": 1}, {"samples": [{"hash": "8vzFEJrDzyj", "uri": "/contracts/8vzFEJrDzyj#product-transfer", "label": "Contingent Value Rights Agreement (Concert Pharmaceuticals, Inc.)", "score": 34.1745376587, "published": true}, {"hash": "gCZt6BZ5Z1t", "uri": "/contracts/gCZt6BZ5Z1t#product-transfer", "label": "Contingent Value Rights Agreement (Sun Pharmaceutical Industries LTD)", "score": 34.0869255066, "published": true}, {"hash": "kSA8OsTbtNK", "uri": "/contracts/kSA8OsTbtNK#product-transfer", "label": "Merger Agreement (Concert Pharmaceuticals, Inc.)", "score": 34.0485954285, "published": true}], "size": 5, "snippet_links": [{"key": "section-48", "type": "clause", "offset": [29, 40]}], "snippet": "has the meaning set forth in Section 4.8.", "hash": "a318f9fdffae6e0ff2f8614eb19ad7f7", "id": 2}, {"samples": [{"hash": "dTRc1Hre1Xi", "uri": "/contracts/dTRc1Hre1Xi#product-transfer", "label": "Contingent Value Rights Agreement (Mannkind Corp)", "score": 36.7700195312, "published": true}, {"hash": "25iKbNjcJUj", "uri": "/contracts/25iKbNjcJUj#product-transfer", "label": "Contingent Value Rights Agreement (Mannkind Corp)", "score": 36.742641449, "published": true}, {"hash": "lBaa7zGdLKq", "uri": "/contracts/lBaa7zGdLKq#product-transfer", "label": "Merger Agreement (scPharmaceuticals Inc.)", "score": 36.6468162537, "published": true}], "size": 4, "snippet_links": [{"key": "exclusive-license", "type": "clause", "offset": [40, 57]}, {"key": "all-or-substantially-all", "type": "clause", "offset": [61, 85]}, {"key": "the-rights", "type": "clause", "offset": [89, 99]}, {"key": "regulatory-approval", "type": "clause", "offset": [132, 151]}, {"key": "the-products", "type": "clause", "offset": [206, 218]}, {"key": "a-third-party", "type": "clause", "offset": [232, 245]}, {"key": "for-clarity", "type": "clause", "offset": [247, 258]}, {"key": "change-of-control-transaction", "type": "clause", "offset": [264, 293]}, {"key": "transactions-with", "type": "clause", "offset": [299, 316]}, {"key": "third-party-service-provider", "type": "clause", "offset": [321, 349]}, {"key": "contract-manufacturers", "type": "definition", "offset": [357, 379]}, {"key": "incidental-contracts", "type": "definition", "offset": [388, 408]}], "snippet": "means any sale, assignment, transfer or exclusive license of all or substantially all of the rights to research, develop, apply for Regulatory Approval for, manufacture, commercialize and otherwise exploit the Products worldwide to a third party. For clarity, any Change of Control Transaction, any transactions with any third party service provider (e.g., contract manufacturers) or any Incidental Contracts shall not constitute a Product Transfer.", "hash": "eb2ddeb56de5a3024c5a07f50641beb1", "id": 3}, {"samples": [{"hash": "24GsFL0kEuM", "uri": "/contracts/24GsFL0kEuM#product-transfer", "label": "Purchase and Sale Agreement", "score": 31.3408622742, "published": true}, {"hash": "4DoG0uGxz7Y", "uri": "/contracts/4DoG0uGxz7Y#product-transfer", "label": "Purchase and Sale Agreement (Medicines Co /De)", "score": 27.3627643585, "published": true}], "size": 4, "snippet_links": [], "snippet": "has the meaning set forth in Section 9.13(b).", "hash": "3e88524c79211d6de28413902099bede", "id": 4}, {"samples": [{"hash": "61fZXweKaK7", "uri": "/contracts/61fZXweKaK7#product-transfer", "label": "Option Agreement (Arvinas, Inc.)", "score": 30.5906906128, "published": true}, {"hash": "67EaGSk7IS1", "uri": "http://ir.arvinas.com/static-files/336b634f-4249-4c72-9e4b-12340fb3bfb0", "label": "ir.arvinas.com", "score": 10.1704311371, "published": false}], "size": 3, "snippet_links": [{"key": "pursuant-to", "type": "clause", "offset": [20, 31]}, {"key": "company-product", "type": "definition", "offset": [40, 55]}, {"key": "a-person", "type": "definition", "offset": [88, 96]}, {"key": "to-the-company", "type": "definition", "offset": [109, 123]}, {"key": "company-subsidiary", "type": "clause", "offset": [132, 150]}], "snippet": "means a transaction pursuant to which a Company Product is (or would be) Transferred to a Person (other than to the Company or to a Company Subsidiary).", "hash": "b7ef1f1cc1ed6bd3690f1f9533ba6beb", "id": 5}, {"samples": [{"hash": "2MPab33fBUY", "uri": "/contracts/2MPab33fBUY#product-transfer", "label": "Asset Purchase Agreement", "score": 21.0095825195, "published": true}], "size": 1, "snippet_links": [], "snippet": "means when:", "hash": "b93df927ea33a78a3407834a6821d707", "id": 6}, {"samples": [{"hash": "jb1en3K4Evu", "uri": "/contracts/jb1en3K4Evu#product-transfer", "label": "License Agreement (Astria Therapeutics, Inc.)", "score": 36.8631074606, "published": true}], "size": 1, "snippet_links": [], "snippet": "has the meaning set forth in Section 14.3.1(h).", "hash": "98eb6820eda06690024e67a7d0c9fab4", "id": 7}, {"samples": [{"hash": "2JzHLqANykN", "uri": "/contracts/2JzHLqANykN#product-transfer", "label": "Asset Purchase Agreement (Fusion Pharmaceuticals Inc.)", "score": 32.1649551392, "published": true}], "size": 1, "snippet_links": [], "snippet": "has the meaning set forth in Section 2.8(e)(iii)(A).", "hash": "4d80bf50eb9ac67532b7f96ff86fd257", "id": 8}, {"samples": [{"hash": "bVaZclMjPUY", "uri": "/contracts/bVaZclMjPUY#product-transfer", "label": "Asset Purchase Agreement", "score": 21.0930862427, "published": true}], "size": 1, "snippet_links": [{"key": "product-transfer-date", "type": "definition", "offset": [4, 25]}, {"key": "in-relation-to", "type": "clause", "offset": [38, 52]}, {"key": "the-territory", "type": "clause", "offset": [53, 66]}, {"key": "final-date", "type": "definition", "offset": [72, 82]}], "snippet": "or \u201cProduct Transfer Date\u201d shall mean in relation to the Territory, the final date upon which all of the following events are achieved when:", "hash": "a6e70577659f22575b7240053aeda915", "id": 9}, {"samples": [{"hash": "77kB3BDeMYT", "uri": "/contracts/77kB3BDeMYT#product-transfer", "label": "Collaboration, Option and License Agreement (Zogenix, Inc.)", "score": 32.1622161865, "published": true}], "size": 1, "snippet_links": [{"key": "with-respect-to", "type": "clause", "offset": [7, 22]}, {"key": "licensed-product", "type": "definition", "offset": [25, 41]}, {"key": "development-program", "type": "clause", "offset": [69, 88]}, {"key": "transfer-of", "type": "clause", "offset": [94, 105]}, {"key": "development-responsibility", "type": "clause", "offset": [106, 132]}, {"key": "the-product", "type": "definition", "offset": [191, 202]}, {"key": "transfer-criteria", "type": "definition", "offset": [203, 220]}], "snippet": "means, with respect to a Licensed Product that was Developed under a Development Program, the transfer of Development responsibility from Tevard to Zogenix following achievement by Tevard of the Product Transfer Criteria for such Licensed Product.", "hash": "2491fa7ba6139183142b09eae33487b4", "id": 10}], "next_curs": "Cl0SV2oVc35sYXdpbnNpZGVyY29udHJhY3RzcjkLEhpEZWZpbml0aW9uU25pcHBldEdyb3VwX3Y1NiIZcHJvZHVjdC10cmFuc2ZlciMwMDAwMDAwYQyiAQJlbhgAIAA=", "definition": {"title": "Product Transfer", "size": 31, "snippet": "is defined in Section 2.5.3.", "id": "product-transfer", "examples": ["Arch will claim CENVAT on all the materials/services, wherever applicable and any benefit which may be available to or obtained by Arch pertaining to CENVAT or otherwise shall be taken into account while computing the <strong>Product Transfer</strong> Price under Section 1.1.", "Following any <strong>Product Transfer</strong> to a Person other than a Qualified Transferee, Parent shall remain secondarily liable for any obligations of Parent set forth in this Agreement.", "RESPONSIBILITIES &amp; OBLIGATIONS ABVC will be responsible for conducting the clinical development of the Licensed Product outside Territory and communicating the results as part of the <strong>Product Transfer</strong> (PT), which includes delivering the Licensed Product sufficient to support the clinical studies in Territory, delivering associated documents, manufacturing protocols, QC protocols, to enable ONCOX to develop and commercialize the Licensed Product in Territory.", "With respect to Products dispensed during the calendar quarter in which Closing occurs, Seller shall be responsible for making such rebate payments, but the amount of such payments shall be prorated between Buyer and Seller based on the number of days remaining in said quarter as of thirty (30) days following the <strong>Product Transfer</strong> Date, or the end of that calendar quarter, whichever is earlier.", "Unless and until a <strong>Product Transfer</strong> occurs, the Parent shall remain responsible for paying any and all Milestone Payments in accordance with Section 2.4 and Section 4.2 upon the achievement of the corresponding Milestone, if achieved by the Parent or any of its Affiliates or any of their licensees or sublicensees to which Parent or any of its Affiliates have granted rights to perform the applicable activities, on or before the date specified for the applicable Milestone.", "Adaptec may exercise such option, by giving written notice to Roxio after such transfer, during such time as Roxio holds such Wild File Patents and subject to such restrictions, and, if any such restrictions have been agreed to, including with such notice a copy of the relevant sections of the <strong>Product Transfer</strong> Agreement or related agreement that sets forth such restrictions.", "The Agency shall only disclose the information on a need to know basis to its staff and the members of the Agency\u2019s Technology and <strong>Product Transfer</strong> Board.", "<strong>Product Transfer</strong> Prices are as set forth in the Data Exhibit and are based on delivery ex works, Itamar&#x27;s Caesarea, Israel facilities, as that term is defined in Incoterms 2010, ICC Rules for the Use of Domestic and International Trade Terms, ICC Publication No. 715EF (the \u201cDelivery Point\u201d).", "VIASPACE purchase orders for Giant King Grass seedlings will be filled at the Final <strong>Product Transfer</strong> Price, plus any amounts described in Section 6.8, below, with any all such amounts being paid by VIASPACE to VGE on or before Delivery.", "Furthermore, Novartis is not responsible for conducting any studies, including clinical and stability studies, concerning the Active Pharmaceutical Ingredients and/or the Product, which may be requested by the Regulatory Authority or any Governmental Authority after the Closing Date, regardless of whether the <strong>Product Transfer</strong> Date has occurred or not."], "related": [["product-trademark", "Product Trademark", "Product Trademark"], ["excluded-transfer", "Excluded Transfer", "Excluded Transfer"], ["type-iii-transfer", "Type III transfer", "Type III transfer"], ["transferring-party", "Transferring Party", "Transferring Party"], ["transfer-student", "Transfer student", "Transfer student"]], "related_snippets": [], "updated": "2025-11-14T05:22:25+00:00"}, "json": true, "cursor": ""}}